We served as lead counsel representing a national pharmaceutical ingredient supplier and its wholly owned subsidiaries in a DOJ investigation of alleged FCA violations concerning inflated Average Wholesale Prices, kickbacks to physicians, and waivers of co-pays. After a several-year investigation based on the filing of four separate qui tams, we negotiated a successful resolution of the litigation that was substantially less than the government’s alleged damages.